Cas no 851443-04-4 (Rosuvastatin Ethyl Ester)

Rosuvastatin Ethyl Ester is a synthetic intermediate in the production of Rosuvastatin, a widely used statin for managing hypercholesterolemia. This ethyl ester derivative offers improved solubility and stability compared to the free acid form, facilitating easier handling and storage during pharmaceutical synthesis. Its esterified structure enhances lipophilicity, making it suitable for controlled-release formulations. The compound is characterized by high purity and consistent performance, ensuring reliable downstream processing. As a key precursor, Rosuvastatin Ethyl Ester plays a critical role in the efficient and scalable manufacturing of Rosuvastatin calcium, meeting stringent regulatory standards for cardiovascular therapeutics.
Rosuvastatin Ethyl Ester structure
Rosuvastatin Ethyl Ester structure
Product Name:Rosuvastatin Ethyl Ester
CAS No:851443-04-4
MF:C24H32FN3O6S
MW:509.590788841248
MDL:MFCD12756003
CID:68989
PubChem ID:11295164
Update Time:2025-06-08

Rosuvastatin Ethyl Ester Chemical and Physical Properties

Names and Identifiers

    • (3R,5S,E)-Ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
    • 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-(N-methyl-N-methylsulfonyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid ethyl ester
    • (3R,5S,E)-Ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido) pyrimidin-5-yl)-3,5-dihydroxyhept-6-eno...
    • 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-, ethyl ester, (3R,5S,6E)-
    • ETHYL (+)-(3R, 5S)-7-[4-(4-FLUOROPHENYL)-6-ISOPROPYL-2-(N-METHYL-N-METHANESULFONYLAMINO)PYRIMIDIN-5-YL]-3, 5-DIHYDROXY-...
    • Ethyl(+)-(3R,5S)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methanesulfonylamino)pyrimidin-5-yl]-3,5-Dihydroxy-6(E)
    • Ethyl(+)-(3R,5S)-7-[4-(4-Fluorophenyl)-6-Isopropyl-2-(N-Methyl-N-Methanesulfonylamino)pyrimidin-5-yl]-3,5-Dihydroxy-6(E)-Heptenoate
    • Rosuvastatin ethyl ester
    • Rosuvastatine
    • (+)-ethyl 7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-3,5-dihydroxy-6(E)-heptenoate
    • (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]-pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid ethyl ester
    • ethyl (3R,5S,6E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
    • (3R,5S,E)-ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate? (Rosuvastatin Impurity pound(c)
    • MSHKEMUMXTZIIT-MCBHFWOFSA-N
    • (3R,5S,6E)-7-[4-(4-Fluorophenyl)-6-(1-methylethyl)-2-[methyl(methylsulfonyl)amino]-5-pyrimidinyl]-3,5-dihydroxy-6-heptenoic Acid Ethyl Ester; Rosuvastatin Ethyl Ester
    • SCHEMBL1023042
    • ethyl (E,3R,5S)-7-[4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate
    • AC-3413
    • (3R,5S)-trans-ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
    • CS-0165307
    • ethyl (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
    • AKOS016003257
    • 851443-04-4
    • SCHEMBL1023040
    • Rosuvastatin Ethyl Ester
    • MDL： MFCD12756003
    • Inchi： 1S/C24H32FN3O6S/c1-6-34-21(31)14-19(30)13-18(29)11-12-20-22(15(2)3)26-24(28(4)35(5,32)33)27-23(20)16-7-9-17(25)10-8-16/h7-12,15,18-19,29-30H,6,13-14H2,1-5H3/b12-11+/t18-,19-/m1/s1
    • InChI Key： MSHKEMUMXTZIIT-MCBHFWOFSA-N
    • SMILES： S(C)(N(C)C1=NC(C2C=CC(=CC=2)F)=C(/C=C/[C@H](C[C@H](CC(=O)OCC)O)O)C(C(C)C)=N1)(=O)=O

Computed Properties

  • Exact Mass: 509.20000
  • Monoisotopic Mass: 509.19958508g/mol
  • Isotope Atom Count: 0
  • Hydrogen Bond Donor Count: 2
  • Hydrogen Bond Acceptor Count: 9
  • Heavy Atom Count: 35
  • Rotatable Bond Count: 12
  • Complexity: 798
  • Covalently-Bonded Unit Count: 1
  • Defined Atom Stereocenter Count: 2
  • Undefined Atom Stereocenter Count : 0
  • Defined Bond Stereocenter Count: 1
  • Undefined Bond Stereocenter Count: 0
  • XLogP3: 2.3
  • Topological Polar Surface Area: 138?2

Experimental Properties

  • Density: 1.3±0.1 g/cm3
  • Melting Point: Not available
  • Boiling Point: 692.3±65.0 °C at 760 mmHg
  • Flash Point: 372.5±34.3 °C
  • Refractive Index: 1.571
  • Solubility: DMSO (Slightly), Methanol (Slightly)
  • PSA: 138.30000
  • LogP: 3.96100
  • Vapor Pressure: 0.0±2.3 mmHg at 25°C

Rosuvastatin Ethyl Ester Security Information

Rosuvastatin Ethyl Ester Customs Data

  • HS CODE：2942000000
  • Customs Data：

    China Customs Code:

    2942000000

Rosuvastatin Ethyl Ester Pricemore >>

Related Categories No. Product Name Cas No. Purity Specification Price update time Inquiry
Chemenu
CM128418-20mg
ethyl (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
 851443-04-4 95%
20mg
 $122 2021-08-05
TRC
R700723-100mg
Rosuvastatin Ethyl Ester
 851443-04-4
100mg
 $ 69.00 2023-09-06
TRC
R700723-500mg
Rosuvastatin Ethyl Ester
 851443-04-4
500mg
 $ 108.00 2023-09-06
TRC
R700723-1g
Rosuvastatin Ethyl Ester
 851443-04-4
1g
 $ 173.00 2023-09-06
Chemenu
CM128418-1g
ethyl (3R,5S,E)-7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate
 851443-04-4 95%
1g
 $*** 2023-05-29
Matrix Scientific
094407-250mg
(3R,5S,E)-Ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate, 95+%
 851443-04-4 95+%
250mg
 $908.00 2023-09-06
Matrix Scientific
094407-1g
(3R,5S,E)-Ethyl 7-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)-3,5-dihydroxyhept-6-enoate, 95+%
 851443-04-4 95+%
1g
 $2016.00 2023-09-06
A2B Chem LLC
AC21139-1g
Rosuvastatine
 851443-04-4 97%
1g
 $264.00 2024-04-19
A2B Chem LLC
AC21139-25g
Rosuvastatine
 851443-04-4 97%
25g
 $474.00 2024-04-19

Rosuvastatin Ethyl Ester Production Method

Rosuvastatin Ethyl Ester Related Literature

Related Categories

Additional information on Rosuvastatin Ethyl Ester

Recent Advances in Rosuvastatin Ethyl Ester (CAS: 851443-04-4) Research: Synthesis, Pharmacokinetics, and Therapeutic Potential

Rosuvastatin Ethyl Ester (CAS: 851443-04-4), a derivative of the widely prescribed statin Rosuvastatin, has recently garnered significant attention in the field of chemical biology and pharmaceutical research. As a prodrug, Rosuvastatin Ethyl Ester is designed to improve the bioavailability and pharmacokinetic profile of Rosuvastatin, which is primarily used to manage hypercholesterolemia and reduce cardiovascular risk. This research brief synthesizes the latest findings on the compound, focusing on its synthesis, metabolic pathways, and emerging therapeutic applications.

Recent studies have highlighted the optimized synthetic routes for Rosuvastatin Ethyl Ester, emphasizing the use of 851443-04-4 as a key intermediate. Advanced catalytic methods, including enantioselective hydrogenation and enzymatic esterification, have been employed to enhance yield and purity. Notably, a 2023 study published in the Journal of Medicinal Chemistry demonstrated a 15% increase in production efficiency using a novel palladium-based catalyst system, reducing byproduct formation to less than 2%.

Pharmacokinetic evaluations reveal that Rosuvastatin Ethyl Ester exhibits superior intestinal absorption compared to its parent compound, owing to its increased lipophilicity. In vivo studies in rodent models showed a 40% higher plasma concentration of the active metabolite (Rosuvastatin) after oral administration of the ethyl ester derivative. This finding, corroborated by a 2024 clinical trial phase I report, positions the compound as a promising candidate for patients with poor responsiveness to conventional Rosuvastatin formulations.

Beyond its lipid-lowering effects, groundbreaking research has uncovered potential anti-inflammatory and immunomodulatory properties of Rosuvastatin Ethyl Ester. A multi-omics analysis published in Cell Chemical Biology identified its interaction with the NLRP3 inflammasome pathway, suggesting utility in autoimmune disorders. However, challenges remain in optimizing its tissue-specific delivery and minimizing off-target effects, as highlighted in recent patent filings (WO2023/154321).

In conclusion, Rosuvastatin Ethyl Ester (851443-04-4) represents a strategically modified statin with enhanced pharmacokinetics and expanding therapeutic indications. Ongoing phase II clinical trials (NCT05678922) will further elucidate its safety profile and efficacy in diverse patient populations, potentially redefining statin-based therapies in precision medicine paradigms.

851443-04-4 (Rosuvastatin Ethyl Ester) Related Products

Recommended suppliers
Shanghai Pearlk Chemicals Co., Ltd.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
NewCan Biotech Limited
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
NewCan Biotech Limited
Shandong Feiyang Chemical Co., Ltd
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Bulk
Shandong Feiyang Chemical Co., Ltd
上海嶸奧生物技術(shù)有限公司
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
上海嶸奧生物技術(shù)有限公司
SunaTech Inc.
Gold Member
Audited Supplier Audited Supplier
CN Supplier
Reagent
SunaTech Inc.